menu
    • menu
    [{"orgOrder":0,"company":"NEC Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NEC Corporation \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NEC Corporation \/ Not Applicable"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"TG4050","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NEC Corporation \/ NEC","highestDevelopmentStatusID":"6","companyTruncated":"NEC Corporation \/ NEC"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"NECVAX-NEO1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NEC Corporation \/ AGC Biologics","highestDevelopmentStatusID":"14","companyTruncated":"NEC Corporation \/ AGC Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by NEC Corporation

    Menu

    NEC Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NEC Corporation

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            NEC Corporation

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NECVAX-NEO1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NEC Bio Therapeutics and AGC Biologics Collaborate on Personalized Cancer Vaccines

                            Details : NEC Bio collaborate with AGC Biologics to support the manufacturing and development of NECVAX-NEO1, which is being evaluated in the early-stage for treatingf solid tumors.

                            Brand Name : NECVAX-NEO1

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 08, 2024

                            Lead Product(s) : NECVAX-NEO1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NEC Corporation

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            NEC Corporation

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TG4050

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Transgene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (Myvac® Platform)

                            Details : First patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. The vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge AI capabilities to customize the ...

                            Brand Name : TG4050

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 21, 2021

                            Lead Product(s) : TG4050

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Transgene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NEC Corporation

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            NEC Corporation

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NEC Publishes Design Blueprints for SARS-Cov-2 Vaccines Using its Artificial Intelligence Technology

                            Details : These AI prediction platforms are based on the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 23, 2020

                            Lead Product(s) : SARS-CoV-2 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth